ALS TDI Advances Two Drugs Toward The Clinic
This article was originally published in The Pink Sheet Daily
Executive Summary
The non-profit research organization, focused on the development of drugs for the treatment of ALS, is making clinical progress on two drugs, one of which is Novartis’ Gilenya.
You may also be interested in...
Scientific Advances Increase Potential For Drugs To Treat ALS
New understanding of the spectrum of CNS disorders and rising interest from biotechs have revealed new targets, new biomarkers and new opportunities to treat the fast-acting and deadly neurodegenerative disease. Add to that an open stakeholder forum hosted by FDA Feb. 25 that could clarify regulatory and clinical expectations, and the tide may be turning on amyotrophic lateral sclerosis.
Biogen Idec Makes A Case For Neurology
Management laid out Biogen's neurology pipeline to investors Nov. 30, but most of the drugs are in early development.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.